Background/Aims: Excessive melanogenesis often causes unaesthetic hyperpigmentation. In a previous report, our group introduced a newly synthesized depigmentary agent, Melasolv™ (3,4,5-trimethoxycinnamate thymol ester). In this study, we demonstrated the significant whitening efficacy of Melasolv using various melanocytes and human skin equivalents as in vitro experimental systems. Methods: The depigmentary effect of Melasolv was tested in melan-a cells (immortalized normal murine melanocytes), α-melanocyte-stimulating hormone (α-MSH)-stimulated B16 murine melanoma cells, primary normal human melanocytes (NHMs), and human skin equivalent (MelanoDerm). The whitening efficacy of Melasolv was further demonstrated by photography, time-lapse microscopy, Fontana-Masson (F&M) staining, and 2-photon microscopy. Results: Melasolv significantly inhibited melanogenesis in the melan-a and α-MSH-stimulated B16 cells. In human systems, Melasolv also clearly showed a whitening effect in NHMs and human skin equivalent, reflecting a decrease in melanin content. F&M staining and 2-photon microscopy revealed that Melasolv suppressed melanin transfer into multiple epidermal layers from melanocytes as well as melanin synthesis in human skin equivalent. Conclusion: Our study showed that Melasolv clearly exerts a whitening effect on various melanocytes and human skin equivalent. These results suggest the possibility that Melasolv can be used as a depigmentary agent to treat pigmentary disorders as well as an active ingredient in cosmetics to increase whitening efficacy.

Keywords:
Melasolv, Melanogenesis, Depigmentary agent, Three-dimensional human skin equivalent
1.
Swalwell H, Latimer J, Haywood RM, Birch-Machin MA: Investigating the role of melanin in UVA/UVB- and hydrogen peroxide-induced cellular and mitochondrial ROS production and mitochondrial DNA damage in human melanoma cells. Free Radic Biol Med 2012;52:626-634.
2.
Briganti S, Camera E, Picardo M: Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res 2003;16:101-110.
3.
Ando H, Kondoh H, Ichihashi M, Hearing V: Approaches to identify inhibitors of melanin biosynthesis via the quality control of tyrosinase. J Invest Dermatol 2007;127:751-761.
4.
Solano F, Briganti S, Picardo M, Ghanem G: Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res 2006;19:550-571.
5.
Kang HH, Rho HS, Hwang JS, Oh SG: Depigmenting activity and low cytotoxicity of alkoxy benzoates or alkoxy cinnamte in cultured melanocytes. Chem Pharm Bull (Tokyo) 2003;51:1085-1088.
6.
Lee ES, Park JH, Lee SW, Hahn J, Lee H, Chae SW, Lee TG, Moon DW, Kim SH: Lipid crystals mechanically stimulate adjacent extracellular matrix in advanced atherosclerotic plaques. Atherosclerosis 2014;37:769-776.
7.
Han M, Giese G, Schmitz-Valckenberg S, Bindewald-Wittich A, Holz FG, Yu J, Bille JF, Niemz MH: Age-related structural abnormalities in the human retina-choroid complex revealed by two-photon excited autofluorescence imaging. J Biomed Opt 2007;12:024012.
8.
Siegrist W, Eberle AN: In situ melanin assay for MSH using mouse B16 melanoma cells in culture. Anal Biochem 1986;159:191-197.
9.
Santiago-Walker A, Li L, Haass NK, Herlyn M: Melanocytes: from morphology to application. Skin Pharmacol Physiol 2009;22:114-121.
10.
Lee CS, Shin YJ, Won C, Lee YS, Park CG, Ye SK, Chung MH: Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells. Biocell 2009;33:107-114.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.